Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The programme aims to enhance access to targeted cancer therapies by identifying actionable genetic mutations in lung cancer patients ...

SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

Ochsner Lafayette General Medical Center performed its first procedure with the Ion robotic-assisted bronchoscopy system; ...

Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...

A study found a "significant" link between the frequency of chest X-ray referrals and improved survival rates for lung cancer ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...